Latest News Releases
CSL’s Global Role in Battling COVID-19
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19
Collaborating on Potential COVID-19 Therapy
Osaka, JAPAN, and King of Prussia, PA, USA
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Our Offer To Help Battle Coronavirus
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
CSL Ranks Among Best Employers for Diversity
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.
CSL at J.P. Morgan's 2020 Healthcare Conference
Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
CSL Continues to Advance R&D Capabilities
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.
CSL Media Statement
CSL statement in response to media reports on case against Joseph Chiao
CSL Limited Celebrates 25 Years on the ASX
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.
$2.5 million CSL Centenary Fellowships announced
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.
CSL to Move Global Headquarters
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Renews Partnership with NYSF
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long STEM literacy.
Nancy Millis building opens at Bio21 Institute
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, incorporating CSL’s Global Hub for Research and Translational Medicine.
Developments in cell-based vaccine technology
CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing
2019 Centenary Fellowship Winners Announced
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we might develop better vaccines against diseases such as tuberculosis.
CSL Donates to Indonesian Relief Operations
CSL today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
CSL a Top 100 Company for Diversity & Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
Senior Manager, Communications
Phone: +61 429 609 762